支持艾滋病护理的行为经济激励措施:乌干达随机对照试验的结果。

IF 2.9 3区 医学 Q3 IMMUNOLOGY JAIDS Journal of Acquired Immune Deficiency Syndromes Pub Date : 2024-07-01 DOI:10.1097/QAI.0000000000003420
Sebastian Linnemayr, Zachary Wagner, Uzaib Y Saya, Chad Stecher, Lillian Lunkuse, Peter Wabukala, Mary Odiit, Barbara Mukasa
{"title":"支持艾滋病护理的行为经济激励措施:乌干达随机对照试验的结果。","authors":"Sebastian Linnemayr, Zachary Wagner, Uzaib Y Saya, Chad Stecher, Lillian Lunkuse, Peter Wabukala, Mary Odiit, Barbara Mukasa","doi":"10.1097/QAI.0000000000003420","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study tests behavioral economics incentives to improve adherence to antiretroviral treatment (ART), with 1 approach being low cost.</p><p><strong>Setting: </strong>Three hundred twenty-nine adults at Mildmay Hospital in Kampala, Uganda, on ART for at least 2 years and showing adherence problems received the intervention for about 15 months until the study was interrupted by a nation-wide COVID-19 lockdown.</p><p><strong>Methods: </strong>We randomized participants into 1 of 3 (1:1:1) groups: usual care (\"control\" group; n = 109) or 1 of 2 intervention groups where eligibility for nonmonetary prizes was based on showing at least 90% electronically measured ART adherence (\"adherence-linked\" group, n = 111) or keeping clinic appointments as scheduled (\"clinic-linked\"; n = 109). After 12 months, participants could win a larger prize for consistently high adherence or viral suppression. Primary outcomes were mean adherence and viral suppression. Analysis was by intention-to-treat using linear regression. This trial is registered with ClinicalTrials.gov, NCT03494777 .</p><p><strong>Results: </strong>Neither incentive arm increased adherence compared with the control; we estimate a 3.9 percentage point increase in \"adherence-linked\" arm [95% confidence interval (CI): -0.70 to 8.60 ( P = 0.10)] and 0.024 in the \"clinic-linked\" arm [95% CI: -0.02 to 0.07 ( P = 0.28)]. For the prespecified subgroup of those with initial low adherence, incentives increased adherence by 7.60 percentage points (95% CI: 0.01, 0.15; P = 0.04, \"adherence-linked\") and 5.60 percentage points (95% CI: -0.01, 0.12; P = 0.10, \"clinic-linked\"). We find no effects on clinic attendance or viral suppression.</p><p><strong>Conclusions: </strong>Incentives did not improve viral suppression or ART adherence overall but worked for the prespecified subgroup of those with initial low adherence. More effectively identifying those in need of adherence support will allow better targeting of this and other incentive interventions.</p>","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":"250-258"},"PeriodicalIF":2.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11192614/pdf/","citationCount":"0","resultStr":"{\"title\":\"Behavioral Economic Incentives to Support HIV Care: Results From a Randomized Controlled Trial in Uganda.\",\"authors\":\"Sebastian Linnemayr, Zachary Wagner, Uzaib Y Saya, Chad Stecher, Lillian Lunkuse, Peter Wabukala, Mary Odiit, Barbara Mukasa\",\"doi\":\"10.1097/QAI.0000000000003420\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study tests behavioral economics incentives to improve adherence to antiretroviral treatment (ART), with 1 approach being low cost.</p><p><strong>Setting: </strong>Three hundred twenty-nine adults at Mildmay Hospital in Kampala, Uganda, on ART for at least 2 years and showing adherence problems received the intervention for about 15 months until the study was interrupted by a nation-wide COVID-19 lockdown.</p><p><strong>Methods: </strong>We randomized participants into 1 of 3 (1:1:1) groups: usual care (\\\"control\\\" group; n = 109) or 1 of 2 intervention groups where eligibility for nonmonetary prizes was based on showing at least 90% electronically measured ART adherence (\\\"adherence-linked\\\" group, n = 111) or keeping clinic appointments as scheduled (\\\"clinic-linked\\\"; n = 109). After 12 months, participants could win a larger prize for consistently high adherence or viral suppression. Primary outcomes were mean adherence and viral suppression. Analysis was by intention-to-treat using linear regression. This trial is registered with ClinicalTrials.gov, NCT03494777 .</p><p><strong>Results: </strong>Neither incentive arm increased adherence compared with the control; we estimate a 3.9 percentage point increase in \\\"adherence-linked\\\" arm [95% confidence interval (CI): -0.70 to 8.60 ( P = 0.10)] and 0.024 in the \\\"clinic-linked\\\" arm [95% CI: -0.02 to 0.07 ( P = 0.28)]. For the prespecified subgroup of those with initial low adherence, incentives increased adherence by 7.60 percentage points (95% CI: 0.01, 0.15; P = 0.04, \\\"adherence-linked\\\") and 5.60 percentage points (95% CI: -0.01, 0.12; P = 0.10, \\\"clinic-linked\\\"). We find no effects on clinic attendance or viral suppression.</p><p><strong>Conclusions: </strong>Incentives did not improve viral suppression or ART adherence overall but worked for the prespecified subgroup of those with initial low adherence. More effectively identifying those in need of adherence support will allow better targeting of this and other incentive interventions.</p>\",\"PeriodicalId\":14588,\"journal\":{\"name\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"volume\":\" \",\"pages\":\"250-258\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11192614/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAI.0000000000003420\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003420","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:这项研究测试了通过行为经济学激励措施提高抗逆转录病毒治疗依从性的方法:本研究测试了行为经济学激励措施,以改善抗逆转录病毒治疗(ART)的依从性,其中一种方法成本较低:乌干达坎帕拉米尔德梅医院的 329 名成年人接受了为期约 15 个月的干预,这些成年人至少接受了两年的抗逆转录病毒疗法,并且在坚持治疗方面存在问题,直到研究因全国范围内的 COVID-19 封锁而中断:我们将参与者随机分为三组(1:1:1):常规护理组("对照 "组,人数=109)或两组干预组,其中一组干预组的非货币奖品资格基于以下条件:电子测量的抗逆转录病毒疗法依从性至少达到 90%("依从性相关 "组,人数=111);或按时预约门诊("门诊相关 "组,人数=109)。12 个月后,如果参与者的依从性或病毒抑制率一直很高,则可赢得更丰厚的奖品。主要结果为平均依从性和病毒抑制率。采用线性回归进行意向治疗分析。该试验已在 ClinicalTrials.gov 登记,编号为 NCT03494777:与对照组相比,两个激励组都没有提高依从性;我们估计 "与依从性挂钩 "组提高了3.9个百分点[95% CI -0.70 至 8.60 (p=0.10)],而 "与临床挂钩 "组提高了0.024个百分点[95% CI -0.02 至 0.07 (p=0.28)]。对于预设的初始依从性较低的亚组,激励措施使依从性提高了 7.60 个百分点(95% CI 0.01,0.15;p=0.04,"与依从性相关")和 5.60 个百分点(95% CI -0.01,0.12;p=0.10,"与诊所相关")。我们没有发现激励措施对就诊率或病毒抑制率有任何影响:总体而言,激励措施并未改善病毒抑制率或抗病毒疗法的依从性,但对初始依从性较低的预设亚组有效。如果能更有效地识别需要坚持治疗支持的人群,就能更有针对性地采取该激励措施和其他激励措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Behavioral Economic Incentives to Support HIV Care: Results From a Randomized Controlled Trial in Uganda.

Background: This study tests behavioral economics incentives to improve adherence to antiretroviral treatment (ART), with 1 approach being low cost.

Setting: Three hundred twenty-nine adults at Mildmay Hospital in Kampala, Uganda, on ART for at least 2 years and showing adherence problems received the intervention for about 15 months until the study was interrupted by a nation-wide COVID-19 lockdown.

Methods: We randomized participants into 1 of 3 (1:1:1) groups: usual care ("control" group; n = 109) or 1 of 2 intervention groups where eligibility for nonmonetary prizes was based on showing at least 90% electronically measured ART adherence ("adherence-linked" group, n = 111) or keeping clinic appointments as scheduled ("clinic-linked"; n = 109). After 12 months, participants could win a larger prize for consistently high adherence or viral suppression. Primary outcomes were mean adherence and viral suppression. Analysis was by intention-to-treat using linear regression. This trial is registered with ClinicalTrials.gov, NCT03494777 .

Results: Neither incentive arm increased adherence compared with the control; we estimate a 3.9 percentage point increase in "adherence-linked" arm [95% confidence interval (CI): -0.70 to 8.60 ( P = 0.10)] and 0.024 in the "clinic-linked" arm [95% CI: -0.02 to 0.07 ( P = 0.28)]. For the prespecified subgroup of those with initial low adherence, incentives increased adherence by 7.60 percentage points (95% CI: 0.01, 0.15; P = 0.04, "adherence-linked") and 5.60 percentage points (95% CI: -0.01, 0.12; P = 0.10, "clinic-linked"). We find no effects on clinic attendance or viral suppression.

Conclusions: Incentives did not improve viral suppression or ART adherence overall but worked for the prespecified subgroup of those with initial low adherence. More effectively identifying those in need of adherence support will allow better targeting of this and other incentive interventions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.80
自引率
5.60%
发文量
490
审稿时长
3-6 weeks
期刊介绍: JAIDS: Journal of Acquired Immune Deficiency Syndromes​ seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
期刊最新文献
Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV. Using machine learning techniques to predict viral suppression among people with HIV. Non-liver malignancies as main cause of mortality after HCV eradication among people living with HIV. Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine. Real-world comparative Analysis of Liposomal Doxorubicin versus Paclitaxel as First-Line Therapy for Kaposi Sarcoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1